Format

Send to

Choose Destination
Anticancer Res. 2018 Apr;38(4):2217-2225.

WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study.

Author information

1
Center for Advanced Cell Therapy, Shinshu University Hospital, Matsumoto, Japan ryu@shinshu-u.ac.jp.
2
Shinshu Cancer Center, Shinshu University Hospital, Matsumoto, Japan.
3
Department of Regenerative Medicine, Kanazawa Medical University, Ishikawa, Japan.
4
Department of Laboratory Medicine, Shinshu University Hospital, Matsumoto, Japan.
5
Department of Gastroenterology and Hepatology, The Jikei University School of Medicine, Kashiwa, Japan.
6
Transfusion and Cell Therapy Unit, Nagasaki University Hospital, Sakamoto, Japan.
7
Department of Advanced Immunotherapeutics, Osaka University Graduate School of Pharmaceutical Sciences, Suita, Japan.
8
Department of Functional Diagnostic Science, Graduate School of Medicine, Osaka University, Suita, Japan.

Abstract

BACKGROUND/AIM:

Wilms' tumor 1 (WT1) is a tumor-associated antigen highly expressed in cancer. We examined the safety of WT1-peptide pulsed dendritic cell (WT1-DC) vaccine in combination with chemotherapy in patients with surgically resected pancreatic cancer.

PATIENTS AND METHODS:

Eight patients with resectable pancreatic cancer undergoing surgery either combined with S-1 or S-1 plus gemcitabine therapy were enrolled. Immunohistochemical analysis of WT1 was performed in 34 cases of pancreatic cancer.

RESULTS:

No serious side-effects were observed, except grade I fever in five and grade I reactions at the injection site in all patients. WT1-specific cytotoxic T-lymphocytes were detected in seven patients, and WT1 and human leukocyte antigen class I antigens were positive in all 34 cases.

CONCLUSION:

Our study clarified the safety and potential acquisition of immunity after vaccination targeting WT1. Further efficacy of WT1-DC vaccine to improve prognosis would be determined by a prospective clinical trial for resectable pancreatic cancer.

KEYWORDS:

DC vaccine; S-1; T cell; WT1; immunotherapy

PMID:
29599342
DOI:
10.21873/anticanres.12464
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center